Your session is about to expire
← Back to Search
Attention Bias Modification for PTSD (SMART Trial)
N/A
Recruiting
Led By Joshua Woolley, MD, PhD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 weeks, 8 weeks
Summary
This trial will compare the effects of attention bias modification (ABM), attention control training (ACT), placebo neutral attention training, and a final control condition with daily questions in 1,897 individuals with clinically significant Post-traumatic Stress Symptoms (PTSS).
Who is the study for?
This trial is for individuals aged 18 to 55 who have significant post-traumatic stress symptoms, as indicated by a score of at least 33 on the PCL-5. Participants must own a smartphone compatible with the study's app and be willing to engage in daily training for two weeks. Those without the required smartphone or current suicidal thoughts cannot participate.
What is being tested?
The study tests four different smartphone-based trainings: attention bias modification, attention control training, placebo neutral attention training, and a control condition involving daily questions. The goal is to see how these affect attention bias and self-reported stress symptoms over eight weeks in nearly 1,900 participants.
What are the potential side effects?
Since this trial involves non-invasive app-based interventions focused on modifying attention patterns related to trauma, there are no direct physical side effects expected from participation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 4 weeks, 8 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 weeks, 8 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in PTSD Checklist-5 (PCL) Score (Before/After Training)
Change in PTSD Checklist-5 (PCL) Score (Follow-up)
Trial Design
7Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Attention Control Training - Word StimuliExperimental Treatment1 Intervention
Attention control training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (i.e. one threat word and one neutral word) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ACT condition, the probe replaces the neutral stimulus 50% of the time, and replaces the threat stimulus the other 50%.
Group II: Attention Bias Modification - Word StimuliExperimental Treatment1 Intervention
Attention bias modification training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threat word and one neutral word) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ABM condition, the probe replaces the neutral stimulus 100% of the time.
Group III: Attention Bias Modification - Face StimuliActive Control1 Intervention
Attention bias modification training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threatening face and one neutral face) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ABM condition, the probe replaces the neutral stimulus 100% of the time.
Group IV: Attention Control Training - Face StimuliActive Control1 Intervention
Attention control training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (one threatening face and one neutral face) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen. In the active ACT condition, the probe replaces the neutral stimulus 50% of the time, and replaces the threat stimulus the other 50%.
Group V: Control - QuestionsPlacebo Group1 Intervention
The Control - Questions condition will only deliver a set of daily questions for participants to answer. Questions will ask about a variety of psychological factors such as mood, stress experiences, daily exercise and more.
Group VI: Placebo Attention Training - Face StimuliPlacebo Group1 Intervention
Placebo attention training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (two neutral faces) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen.
Group VII: Placebo Attention Training - Word StimuliPlacebo Group1 Intervention
Placebo attention training involves a probe detection task as follows: (1) a fixation cross appears on the screen for 500ms; (2) the fixation cross is replaced by two target stimuli (two neutral words) that are displayed at the top and the bottom of the screen for 500ms; (2) the stimuli disappear and a visual probe appears (the letter E or F), in the location of one of the two stimuli until the participant responds to indicate whether the letter was an E or an F using response buttons at the bottom of the phone screen.
Find a Location
Who is running the clinical trial?
San Francisco Veterans Affairs Medical CenterFED
51 Previous Clinical Trials
209,362 Total Patients Enrolled
University of California, San FranciscoLead Sponsor
2,593 Previous Clinical Trials
14,886,053 Total Patients Enrolled
Joshua Woolley, MD, PhDPrincipal InvestigatorUCSF, SFVAMC
2 Previous Clinical Trials
94 Total Patients Enrolled
Joaquin Anguera, PhDPrincipal InvestigatorUniversity of California, San Francisco
1 Previous Clinical Trials
70 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have an Android or iPhone smartphone.You are currently having thoughts or plans of hurting yourself.You have a score of 33 or higher on a posttraumatic stress disorder (PTSD) checklist.You can understand and speak English fluently.
Research Study Groups:
This trial has the following groups:- Group 1: Attention Control Training - Word Stimuli
- Group 2: Attention Bias Modification - Word Stimuli
- Group 3: Control - Questions
- Group 4: Attention Bias Modification - Face Stimuli
- Group 5: Attention Control Training - Face Stimuli
- Group 6: Placebo Attention Training - Face Stimuli
- Group 7: Placebo Attention Training - Word Stimuli
Awards:
This trial has 0 awards, including:Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.